Denosumab for The Treatment of Bone Disease in Solid Tumors and Multiple Myeloma

References

• Vallet S , SmithMR, RajeN. Novel bone-targeted strategies in oncology. Clin. Cancer Res.16(16), 4084–4093 (2010).
   PubMed Web of Science ®Google Scholar
• Boyle WJ , SimonetWS, LaceyDL. Osteoclast differentiation and activation. Nature423(6937), 337–342 (2003).
   PubMed Web of Science ®Google Scholar
• Lacey DL , BoyleWJ, SimonetWSet al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov.11(5), 401–419 (2012).
   PubMed Web of Science ®Google Scholar
• Mancino AT , KlimbergVS, YamamotoM, ManolagasSC, AbeE. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J. Surg. Res.100(1), 18–24 (2001).
   PubMed Web of Science ®Google Scholar
• Pearse RN , SordilloEM, YaccobySet al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl Acad. Sci. USA98(20), 11581–11586 (2001).
   PubMed Web of Science ®Google Scholar
• Croucher PI , McDonaldMM, MartinTJ. Bone metastasis: the importance of the neighbourhood. Nat. Rev. Cancer16(6), 373–386 (2016).
   PubMed Web of Science ®Google Scholar
• Lu Y , CaiZ, XiaoGet al. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res.67(8), 3646–3653 (2007).
   PubMed Web of Science ®Google Scholar
• Giuliani N , MorandiF, TagliaferriSet al. Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood107(2), 841–842 (2006).
   PubMed Web of Science ®Google Scholar
• Wei S , KitauraH, ZhouP, RossFP, TeitelbaumSL. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest.115(2), 282–290 (2005).
   PubMed Web of Science ®Google Scholar
• Nakchbandi IA , WeirEE, InsognaKL, PhilbrickWM, BroadusAE. Parathyroid hormone-related protein induces spontaneous osteoclast formation via a paracrine cascade. Proc. Natl Acad. Sci. USA97(13), 7296–7300 (2000).
   PubMed Web of Science ®Google Scholar
• Mundy GR . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer2(8), 584–593 (2002).
   PubMed Web of Science ®Google Scholar
• Favus MJ . Bisphosphonates for osteoporosis. N. Engl. J. Med.363(21), 2027–2035 (2010).
   PubMed Web of Science ®Google Scholar
• Gralow JR , BiermannJS, FarookiAet al. NCCN Task Force Report: bone health in cancer care. J. Natl Compr. Canc. Netw.7(Suppl. 3), S1–S32; quiz S33–S35 (2009).
   PubMedGoogle Scholar
• Rosen LS , GordonD, KaminskiMet al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer98(8), 1735–1744 (2003).
   PubMed Web of Science ®Google Scholar
• Rosen LS , GordonD, TchekmedyianSet al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial – the zoledronic acid lung cancer and other solid tumors study group. J. Clin. Oncol.21(16), 3150–3157 (2003).
   PubMed Web of Science ®Google Scholar
• Saad F , GleasonDM, MurrayRet al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst.94(19), 1458–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Wong MH , StocklerMR, PavlakisN. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst. Rev. (2), CD003474 (2012).
   PubMed Web of Science ®Google Scholar
• Kyle RA , GertzMA, WitzigTEet al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc.78(1), 21–33 (2003).
   PubMed Web of Science ®Google Scholar
• Moreau P , AttalM, CaillotDet al. Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J. Clin. Oncol.35(25), 2911–2918 (2017).
   PubMed Web of Science ®Google Scholar
• Morgan GJ , DaviesFE, GregoryWMet al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet376(9757), 1989–1999 (2010).
   PubMed Web of Science ®Google Scholar
• Morgan GJ , ChildJA, GregoryWMet al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol.12(8), 743–752 (2011).
   PubMed Web of Science ®Google Scholar
• Morgan GJ , DaviesFE, GregoryWMet al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood119(23), 5374–5383 (2012).
   PubMed Web of Science ®Google Scholar
• Kumar SK , CallanderNS, AlsinaMet al. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw.15(2), 230–269 (2017).
   PubMed Web of Science ®Google Scholar
• Terpos E , MorganG, DimopoulosMAet al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J. Clin. Oncol.31(18), 2347–2357 (2013).
   PubMed Web of Science ®Google Scholar
• Baron R , FerrariS, RussellRG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone48(4), 677–692 (2011).
   PubMed Web of Science ®Google Scholar
• Cummings SR , San MartinJ, McclungMRet al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med.361(8), 756–765 (2009).
   PubMed Web of Science ®Google Scholar
• Coleman RE , MajorP, LiptonAet al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol.23(22), 4925–4935 (2005).
   PubMed Web of Science ®Google Scholar
• Brown JE , CookRJ, MajorPet al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl Cancer Inst.97(1), 59–69 (2005).
   PubMed Web of Science ®Google Scholar
• Lipton A , StegerGG, FigueroaJet al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin. Cancer Res.14(20), 6690–6696 (2008).
   PubMed Web of Science ®Google Scholar
• Lipton A , StegerGG, FigueroaJet al. Randomized active-controlled Phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J. Clin. Oncol.25(28), 4431–4437 (2007).
   PubMed Web of Science ®Google Scholar
• Body JJ , FaconT, ColemanREet al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res.12(4), 1221–1228 (2006).
   PubMed Web of Science ®Google Scholar
• Fizazi K , LiptonA, MarietteXet al. Randomized Phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol.27(10), 1564–1571 (2009).
   PubMed Web of Science ®Google Scholar
• Stopeck AT , LiptonA, BodyJJet al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol.28(35), 5132–5139 (2010).
   PubMed Web of Science ®Google Scholar
• Martin M , BellR, BourgeoisHet al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized Phase III trial of denosumab versus zoledronic acid. Clin. Cancer Res.18(17), 4841–4849 (2012).
   PubMed Web of Science ®Google Scholar
• Fizazi K , CarducciM, SmithMet al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet377(9768), 813–822 (2011).
   PubMed Web of Science ®Google Scholar
• Henry DH , CostaL, GoldwasserFet al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol.29(9), 1125–1132 (2011).
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S , Von MoosR, FallowfieldLJet al. Clinical benefit in patients with metastatic bone disease: results of a Phase III study of denosumab versus zoledronic acid. Ann. Oncol.23(12), 3045–3051 (2012).
   PubMed Web of Science ®Google Scholar
• Perazella MA , MarkowitzGS. Bisphosphonate nephrotoxicity. Kidney Int.74(11), 1385–1393 (2008).
   PubMed Web of Science ®Google Scholar
• Rosen LS , GordonD, KaminskiMet al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J.7(5), 377–387 (2001).
   PubMed Web of Science ®Google Scholar
• Kyle RA , YeeGC, SomerfieldMRet al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J. Clin. Oncol.25(17), 2464–2472 (2007).
   PubMed Web of Science ®Google Scholar
• Lipton A , FizaziK, StopeckATet al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, Phase III trials. Eur. J. Cancer48(16), 3082–3092 (2012).
   PubMed Web of Science ®Google Scholar
• Raje N , WooSB, HandeKet al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin. Cancer Res.14(8), 2387–2395 (2008).
   PubMed Web of Science ®Google Scholar
• Woo SB , HellsteinJW, KalmarJR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med.144(10), 753–761 (2006).
   PubMed Web of Science ®Google Scholar
• Saad F , BrownJE, Van PoznakCet al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled Phase III trials in cancer patients with bone metastases. Ann. Oncol.23(5), 1341–1347 (2012).
   PubMed Web of Science ®Google Scholar
• Stopeck AT , FizaziK, BodyJJet al. Safety of long-term denosumab therapy: results from the open label extension phase of two Phase III studies in patients with metastatic breast and prostate cancer. Support. Care Cancer24(1), 447–455 (2016).
   PubMed Web of Science ®Google Scholar
• Huynh AL , BakerST, StewardsonAJ, JohnsonDF. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol. Drug Saf.25(11), 1274–1278 (2016).
   PubMed Web of Science ®Google Scholar
• Dave V , ChiangCY, BoothJ, MountPF. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4–5. Am. J. Nephrol.41(2), 129–137 (2015).
   PubMed Web of Science ®Google Scholar
• Yerram P , KansagraS, AbdelghanyO. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis. J. Oncol. Pharm. Pract.23(3), 179–184 (2017).
   PubMed Web of Science ®Google Scholar
• Raje N , Vadhan-RajS, WillenbacherWet al. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized Phase III trial. Blood Cancer J.6, e378 (2016).
   PubMed Web of Science ®Google Scholar
• Raje N , TerposE, WillenbacherWet al. An international randomized, double blind trial comparing denosumab with zoledronic acid for the treatment of bone disease in patients with newly diagnosed multiple myeloma. Presented at: International Myeloma Workshop. Santiago, Chile, 11–12 August 2017 ( Abstract OPO-046).
   Google Scholar
• Van Der Heijden L , DijkstraPDS, BlayJY, GelderblomH. Giant cell tumour of bone in the denosumab era. Eur. J. Cancer77, 75–83 (2017).
   PubMed Web of Science ®Google Scholar
• Lau YS , SabokbarA, GibbonsCL, GieleH, AthanasouN. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum. Pathol.36(9), 945–954 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas D , HenshawR, SkubitzKet al. Denosumab in patients with giant-cell tumour of bone: an open-label, Phase II study. Lancet Oncol.11(3), 275–280 (2010).
   PubMed Web of Science ®Google Scholar
• Chawla S , HenshawR, SeegerLet al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, Phase II study. Lancet Oncol.14(9), 901–908 (2013).
   PubMed Web of Science ®Google Scholar
• Smith MR , SaadF, ColemanRet al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a Phase III, randomised, placebo-controlled trial. Lancet379(9810), 39–46 (2012).
   PubMed Web of Science ®Google Scholar
• Smith MR , SaadF, OudardSet al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J. Clin. Oncol.31(30), 3800–3806 (2013).
   PubMed Web of Science ®Google Scholar
• Wirth M , TammelaT, CicaleseVet al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur. Urol.67(3), 482–491 (2015).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group . Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet386(10001), 1353–1361 (2015).
   PubMed Web of Science ®Google Scholar
• Dhesy-Thind S , FletcherGG, BlanchettePSet al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol.35(18), 2062–2081 (2017).
   PubMed Web of Science ®Google Scholar